Friday 7 April | |
no events scheduled | |
Monday 10 April | |
no events scheduled | |
Tuesday 11 April | |
Devolver Digital Inc | Full Year Results |
JTC PLC | Full Year Results |
Wednesday 12 April | |
Argentex Group PLC | Q3 Results |
DP Eurasia NV | Full Year Results |
Everyman Media Group PLC | Full Year Results |
LBG Media PLC | Full Year Results |
Tharisa PLC | Trading Statement |
Thursday 13 April | |
Brooks Macdonald Group PLC | Trading Statement |
Churchill China PLC | Full Year Results |
Destiny Pharma PLC | Full Year Results |
discoverIE Group PLC | Trading Statement |
Foresight Group Holdings Ltd | Trading Statement |
Imperial Brands PLC | Trading Statement |
LSL Property Services PLC | Full Year Results |
Norcros PLC | Trading Statement |
PZ Cussons PLC | Trading Statement |
Tesco PLC | Full Year Results |
XP Power Ltd | Trading Statement |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
IN BRIEF: Destiny Pharma presents "exciting" data for ringworm drug
Destiny Pharma PLC - biotechnology company, focused on developing and commercialising medicines for life-threatening infections - Announces new data on one of its XF Drug Platform compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection. Says ringworm affects up to one in four people worldwide. XF-70 is a member of a novel class of antimicrobial drugs. Says drug has been shown "to have a rapid bactericidal activity even within biofilms, and is structurally related to the company's leading drug, XF-73 which is being developed for the prevention of post-surgical staphylococcal infections."
Read more